Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1471-2407

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain ; volume:18 ; number:1 ; day:30 ; month:1 ; year:2018 ; pages:1-10 ; date:12.2018
BMC cancer ; 18, Heft 1 (30.1.2018), 1-10, 12.2018

Keyword: Krebs
Onkologie

Creator: Arriola, Edurne

Contributor: García Gómez, Ramón
Diz, Pilar
Majem, Margarita
Martínez Aguillo, Maite
Valdivia, Javier
Paredes, Alfredo
Sánchez-Torres, José Miguel
Peralta Muñoz, Sergio
Barneto, Isidoro
Gutierrez, Vanesa
Andrade Santiago, Jesús Manuel
Aparisi, Francisco
Isla, Dolores
Ponce, Santiago
Vicente Baz, David
Artal, Angel
Amador, Mariluz
Provencio, Mariano
SpringerLink (Online service)

DOI: 10.1186/s12885-018-4004-7

URN: urn:nbn:de:1111-20180327566

Rights: Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 31.07.2025, 4:58 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Arriola, Edurne
García Gómez, Ramón
Diz, Pilar
Majem, Margarita
Martínez Aguillo, Maite
Valdivia, Javier
Paredes, Alfredo
Sánchez-Torres, José Miguel
Peralta Muñoz, Sergio
Barneto, Isidoro
Gutierrez, Vanesa
Andrade Santiago, Jesús Manuel
Aparisi, Francisco
Isla, Dolores
Ponce, Santiago
Vicente Baz, David
Artal, Angel
Amador, Mariluz
Provencio, Mariano
SpringerLink (Online service)

Other Objects (12)

Aufsatzsammlung

EGFR exon 20 insertion mutations in NSCLC

Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations

Pyrosequencing, a method approved to detect the two major EGFR mutations for anti EGFR therapy in NSCLC

Rare oncogenic alterations in NSCLC—focus on atypical EGFR mutations : Invited short review

Intratumoral heterogeneity of EGFR-activating mutations in advanced NSCLC patients at the single-cell level

Comparison between Vinorelbine–Carboplatin and Vinorelbine–Cisplatin in Stage III–IV EGFR Mutations-Negative NSCLC

Sulforaphane attenuates EGFR signaling in NSCLC cells

NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation

Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations

Aggressive progression to EGFR tyrosine kinase inhibitors in advanced NSCLC patients: concomitant mutations, prognostic indicator and subsequent management

Comprehensive analysis of NGS and ARMS-PCR for detecting EGFR mutations based on 4467 cases of NSCLC patients

Osimertinib : Therapieplanung und Therapiesequenzen beim fortgeschrittenen EGFR-mutierten NSCLC

Aufsatzsammlung

EGFR exon 20 insertion mutations in NSCLC

Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations

Pyrosequencing, a method approved to detect the two major EGFR mutations for anti EGFR therapy in NSCLC

Rare oncogenic alterations in NSCLC—focus on atypical EGFR mutations : Invited short review

Intratumoral heterogeneity of EGFR-activating mutations in advanced NSCLC patients at the single-cell level

Comparison between Vinorelbine–Carboplatin and Vinorelbine–Cisplatin in Stage III–IV EGFR Mutations-Negative NSCLC

Sulforaphane attenuates EGFR signaling in NSCLC cells

NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation

Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations

Aggressive progression to EGFR tyrosine kinase inhibitors in advanced NSCLC patients: concomitant mutations, prognostic indicator and subsequent management

Comprehensive analysis of NGS and ARMS-PCR for detecting EGFR mutations based on 4467 cases of NSCLC patients

Osimertinib : Therapieplanung und Therapiesequenzen beim fortgeschrittenen EGFR-mutierten NSCLC

Aufsatzsammlung

EGFR exon 20 insertion mutations in NSCLC

Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations

Pyrosequencing, a method approved to detect the two major EGFR mutations for anti EGFR therapy in NSCLC

Rare oncogenic alterations in NSCLC—focus on atypical EGFR mutations : Invited short review

Intratumoral heterogeneity of EGFR-activating mutations in advanced NSCLC patients at the single-cell level

Comparison between Vinorelbine–Carboplatin and Vinorelbine–Cisplatin in Stage III–IV EGFR Mutations-Negative NSCLC

Sulforaphane attenuates EGFR signaling in NSCLC cells

NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation

Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations

Aggressive progression to EGFR tyrosine kinase inhibitors in advanced NSCLC patients: concomitant mutations, prognostic indicator and subsequent management

Comprehensive analysis of NGS and ARMS-PCR for detecting EGFR mutations based on 4467 cases of NSCLC patients

Osimertinib : Therapieplanung und Therapiesequenzen beim fortgeschrittenen EGFR-mutierten NSCLC

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain

Object Details

References and Relationships

Classification and Topics

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

EGFR exon 20 insertion mutations in NSCLC

Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations

Pyrosequencing, a method approved to detect the two major EGFR mutations for anti EGFR therapy in NSCLC

Rare oncogenic alterations in NSCLC—focus on atypical EGFR mutations : Invited short review

Intratumoral heterogeneity of EGFR-activating mutations in advanced NSCLC patients at the single-cell level

Comparison between Vinorelbine–Carboplatin and Vinorelbine–Cisplatin in Stage III–IV EGFR Mutations-Negative NSCLC

Sulforaphane attenuates EGFR signaling in NSCLC cells

NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation

Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations

Aggressive progression to EGFR tyrosine kinase inhibitors in advanced NSCLC patients: concomitant mutations, prognostic indicator and subsequent management

Comprehensive analysis of NGS and ARMS-PCR for detecting EGFR mutations based on 4467 cases of NSCLC patients

Osimertinib : Therapieplanung und Therapiesequenzen beim fortgeschrittenen EGFR-mutierten NSCLC

EGFR exon 20 insertion mutations in NSCLC

Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations

Pyrosequencing, a method approved to detect the two major EGFR mutations for anti EGFR therapy in NSCLC

Rare oncogenic alterations in NSCLC—focus on atypical EGFR mutations : Invited short review

Intratumoral heterogeneity of EGFR-activating mutations in advanced NSCLC patients at the single-cell level

Comparison between Vinorelbine–Carboplatin and Vinorelbine–Cisplatin in Stage III–IV EGFR Mutations-Negative NSCLC

Sulforaphane attenuates EGFR signaling in NSCLC cells

NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation

Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations

Aggressive progression to EGFR tyrosine kinase inhibitors in advanced NSCLC patients: concomitant mutations, prognostic indicator and subsequent management

Comprehensive analysis of NGS and ARMS-PCR for detecting EGFR mutations based on 4467 cases of NSCLC patients

Osimertinib : Therapieplanung und Therapiesequenzen beim fortgeschrittenen EGFR-mutierten NSCLC

EGFR exon 20 insertion mutations in NSCLC

Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations

Pyrosequencing, a method approved to detect the two major EGFR mutations for anti EGFR therapy in NSCLC

Rare oncogenic alterations in NSCLC—focus on atypical EGFR mutations : Invited short review

Intratumoral heterogeneity of EGFR-activating mutations in advanced NSCLC patients at the single-cell level

Comparison between Vinorelbine–Carboplatin and Vinorelbine–Cisplatin in Stage III–IV EGFR Mutations-Negative NSCLC

Sulforaphane attenuates EGFR signaling in NSCLC cells

NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation

Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations

Aggressive progression to EGFR tyrosine kinase inhibitors in advanced NSCLC patients: concomitant mutations, prognostic indicator and subsequent management

Comprehensive analysis of NGS and ARMS-PCR for detecting EGFR mutations based on 4467 cases of NSCLC patients

Osimertinib : Therapieplanung und Therapiesequenzen beim fortgeschrittenen EGFR-mutierten NSCLC

Related objects

Reset password